title: N-cadherin expression in breast cancer: correlation with an aggressive histologic variant--invasive micropapillary carcinoma.
abstract: Upregulation of N-cadherin in epithelial tumor cells has been shown to contribute to the invasive/metastatic phenotype. It remains however to be determined whether N-cadherin is increased in human breast cancers with enhanced malignant potential. We examined a large number of invasive breast cancer specimens (n = 114) for N- and E-cadherin. These specimens compared invasive duct carcinomas (IDCs) of varying histologic grades with an aggressive subtype, invasive micropapillary carcinoma of the breast (MPAP), which has a high propensity for lymphatic invasion and lymph node metastasis. Staining scores for N- and E-cadherin were compared between non-MPAP and MPAP IDCs, and between the invasive and ductal carcinoma in situ (DCIS) of each IDC using statistical analysis. We found that N-cadherin was expressed in 76% of MPAP and 52% of non-MPAP carcinomas, and E-cadherin in 57% of MPAP and 36% of non-MPAP tumors. More MPAP (25%) compared to non-MPAP (5%) tumors expressed both cadherins. Of the two cadherins, N-cadherin was significantly associated with MPAP tumors (p = 0.033) compared to E-cad (p = 0.171). Moreover, in the majority of tumors that were positive for N-cadherin, the staining scores were increased in the IDC relative to intraductal components, and this effect was more dramatic in the MPAP carcinomas. This difference for N-cadherin was greater than the corresponding difference for E-cadherin in the MPAP group (p = 0.005), whereas such changes were not significant in the non-MPAP group (p = 0.10). Thus, N-cadherin is associated with tumor aggressiveness and metastatic potential and may contribute to tumor progression.
authors.affiliation: Department of Pathology, Mount Sinai School of Medicine, New York, NY, USA.
authors.forename: Chandandeep
authors.initials: C
authors.lastname: Nagi
authors.forename: Mitchell
authors.initials: M
authors.lastname: Guttman
authors.forename: Shabnam
authors.initials: S
authors.lastname: Jaffer
authors.forename: Rui
authors.initials: R
authors.lastname: Qiao
authors.forename: Rinat
authors.initials: R
authors.lastname: Keren
authors.forename: Aymara
authors.initials: A
authors.lastname: Triana
authors.forename: Maomi
authors.initials: M
authors.lastname: Li
authors.forename: James
authors.initials: J
authors.lastname: Godbold
authors.forename: Ira J
authors.initials: IJ
authors.lastname: Bleiweiss
authors.forename: Rachel B
authors.initials: RB
authors.lastname: Hazan
mesh_terms: D015703:Antigens, CD; D001943:Breast Neoplasms / Q000473:pathology*; D015820:Cadherins / Q000096:biosynthesis* / Q000235:genetics; D018270:Carcinoma, Ductal, Breast / Q000473:pathology*; D002291:Carcinoma, Papillary / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D009361:Neoplasm Invasiveness; D010641:Phenotype; D015854:Up-Regulation
chemical_list: D015703:Antigens, CD; C050361:CDH2 protein, human; D015820:Cadherins